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MicroRNAs (miRNAs), small nucleotide sequences that control gene transcription, have
the potential to serve an expanded function as indicators in the diagnosis and progression
of neurological disorders. Studies involving debilitating neurological diseases such as,
Alzheimer’s disease, multiple sclerosis, traumatic brain injuries, Parkinson’s disease
and CNS tumors, already provide validation for their clinical diagnostic use. These
small nucleotide sequences have several features, making them favorable candidates
as biomarkers, including function in multiple tissues, stability in bodily fluids, a role in
pathogenesis, and the ability to be detected early in the disease course. Cerebrospinal
fluid, with its cell-free environment, collection process that minimizes tissue damage,
and direct contact with the brain and spinal cord, is a promising source of miRNA in the
diagnosis of many neurological disorders. Despite the advantages of miRNA analysis,
current analytic technology is not yet affordable as a clinically viable diagnostic tool and
requires standardization. The goal of this review is to explore the prospective use of CSF
miRNA as a reliable and affordable biomarker for different neurological disorders.
Keywords: MicroRNA, biomarker, cerebrospinal fluid (CSF), central nervous system (CNS), neurodegenerative
disease
INTRODUCTION
MicroRNAs (miRNA) are small, noncoding RNA fragments approximately 22 nucleotides long
involved in post-transcriptional regulation of gene expression (Guan et al., 2010; Gallego et al.,
2012; Cheng et al., 2013). After processing by endonucleases (Cheng et al., 2013; Freischmidt et al.,
2013), the resultant single-stranded miRNAs combine with other macromolecules to form RNA-
induced silencing complexes (RISC). These RISCs target complementary messenger RNA (mRNA)
strands for degradation, altering cellular function (Cheng et al., 2013; Freischmidt et al., 2013).
MiRNAs are thought to have widespread action as more than 1500 identified miRNAs have been
shown to affect the expression of 30–60% or more of all genes (Siegel et al., 2012; Ksiazek-Winiarek
et al., 2013; Sheinerman and Umansky, 2013; Cloutier et al., 2015). MiRNA plays a role in virtually
all cellular functions, such as cell proliferation, differentiation, and importantly apoptosis (Guan
et al., 2010; Siegel et al., 2012; Ksiazek-Winiarek et al., 2013). Additionally, miRNAs are widely
present in all body tissues and fluids such as plasma, serum, urine, saliva, milk and CSF (Siegel
et al., 2012; Galimberti et al., 2014).
Various miRNAs subtypes are differently expressed among the organs of the body and within
the organs themselves. For example, a patient with Alzheimer’s disease (AD) will express a different
miRNA profile in the medial frontal gyrus, hippocampus, and cerebellum (Cogswell et al., 2008).
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Due to its pervasiveness, stability in bodily fluids, and
dysregulation in early disease course, miRNA could be
considered a reliable biomarker.
In our analysis, we explored the recent history of serum
and CSF protein biomarkers, discussed the advantages of CSF
miRNA, and examined the utility of CSF miRNA in CNS disease
management.
METHODS
In assessing the reliability of miRNA as a biomarker, we
conducted an extended review of literature on CSF miRNA
in CNS disorders, published within the last 5 years. Choice
landmark studies were also included.
Serum and CSF Protein Biomarkers
Serum and CSF protein biomarkers are able to provide a fast
and accurate diagnosis of various diseases. For example,
CSF IL-8 and serum TNFα, are considered sensitive
markers of neuroinflammation (Maxeiner et al., 2014).
Furthermore, another well-studied CSF biomarker, IL-6,
along with IL-8 have been found to be elevated in patients
with depression and delirium (van Munster et al., 2008;
van den Boogaard et al., 2011; Liu et al., 2013; Kern et al.,
2014).
CSF and serum biomarkers also have shown predictive
value in evaluating neurologic disease progression. Czeiter
et al. demonstrated that, serum and CSF GFAP_24S levels
facilitated traumatic brain injury prognosis alongside the
IMPACT calculator (Czeiter et al., 2012). Several studies
have also investigated AD biomarker prognostic potential,
including the ability to track cognitive decline post-surgery
and progression into AD (Ackermann et al., 2014). Two
such CSF biomarkers, neurogranin and tryptic peptide SNAP-
25, should be able to track AD progression. Furthermore,
neurogranin specifically identifies MCI patients at risk for
developing AD (Brinkmalm et al., 2014; Kvartsberg et al.,
2014).
CSF protein biomarkers, α2HS glycoprotein, α1
antichymotrypsin, and α1beta glycoprotein, may predict
the benefit of ventriculoperitoneal shunt for patients with
normal pressure hydrocephalus (NPH) (Scollato et al., 2010).
NPH patients with improved shunt response also have been
linked to significantly lower CSF levels of sAPPα and sAPPβ
(Pyykö et al., 2014).
Although these protein biomarkers have promising
diagnostic, prognostic, and therapeutic benefits, recent
literature explores their limitations. Interestingly, only
77.2% of 2357 AD patients expressed disease related CSF
Aβ and either T-tau or P-tau protein values (Hoglund et al.,
2015; Rosén et al., 2015). MiRNA appears to predict and
diagnose AD with greater sensitivity, even during mild
cognitive impairment. For example, Alexandrov et al. noticed
miR-9, miR-125b, miR-146b, and miR-155 upregulation
in the diseased state when no significant correlation
was established between Aβ and AD (Alexandrov et al.,
2012).
Advantages of Using miRNA as a
Biomarker
Because of its widespread action and presence, miRNA profile
changes enable the identification of many pathological processes,
including malignancies and cardiovascular and neurological
diseases (Calin et al., 2002; Bonauer et al., 2010; Siegel et al.,
2012).
MiRNAs’ stability is a promising biomarker quality.
Interestingly, Siegel demonstrated a small percent of circulating
miRNAs are protected from degradation due to their inclusion
in small vesicles known as exomes; furthermore, peripheral
miRNAs included in RISC complexes avoid degradation by
RNAses (Siegel et al., 2012). MiRNA is unique in playing a
central role in gene regulation. Schramedei et al. found miR-
21 to be a key oncogenic regulator, downregulating tumor
suppressors ANP32A and SMARCA4 (Schramedei et al.,
2011). Thus, miR-21 could be a more reliable indicator of
disease progression than other tangential biomarkers in the
progression of cancers, like CNS tumors. CSF elevation of let-7b,
a miRNA precursor, is correlated with AD. When administered
in vitro, let-7b was shown to proportionally decrease neuronal
survival while sparing cell lines containing mutated TLR7 or
downstream proteins. Lehmann et al. therefore concluded that
let-7b causes neurodegeneration in AD through activation of
Toll-like Receptor 7 (Lehmann et al., 2012). Ghidoni et al.
linked a decreased miR-107 in early AD to BACE1, a pathogenic
compound in AD (Ghidoni et al., 2011). Unfortunately AD
clinical manifestations and post-mortem diagnosis often overlap
with other forms of dementia such as frontotemporal or Lewy
body dementia (Humpel, 2011). Moreover, observable symptoms
manifest late in the clinical course impairing early diagnosis
and prevention. Other potential biomarkers often appear in
much later stages of the disease when neuronal damage has
already occurred (Kim et al., 2014). Similar to AD, amyotrophic
lateral sclerosis (ALS) identification also relies heavily on clinical
presentation, responsible for misdiagnosis in 8–44% of cases
(Cloutier et al., 2015).
CSF As a Source of miRNA
In patients with neurological disorders, CSF is the ideal source
of miRNA, its profile being identical to that of the brain tissue
because of its close proximity. CSF sampling from lumbar
puncture is often standard procedure for the diagnosis of MS
and ALS (Polman et al., 2005; The ALS Association, 2015). Even
though tissue biopsy may be more accurate than CSF collection,
CSF sampling has the benefit of being much less invasive.
CSF Processing
Method of extraction of CSF usually varies. As a standard
procedure, after CSF is collected, centrifugation (500× g, 10min,
and room temperature) needs to be performed within 60min
after collection in order to remove cells and debris. Storage of
centrifuged samples is usually at −80◦C. Baraniskin et al. (2011)
MicroRNA can be extracted using different kits on the market,
and manufacturer instructions have to be followed carefully in
order to yield themaximumRNApossible. Although 1mL of CSF
only yields 15–30 ng of total RNA, Burgos et al. reported that is
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possible to obtain reproducible results from as little as 0.5mL of
human CSF (Burgos et al., 2013).
MiRNA can also be isolated from amultitude of blood sources,
including serum, plasma, leukocytes, and whole blood samples,
establishing its effectiveness as a biomarker (Cheng et al., 2013;
De Felice et al., 2014). While both CSF and serum miRNA
correlate well with many pathological processes, blood sources
are often preferred over CSF sources because they are less
invasive and accessible (De Felice et al., 2014). Within the context
of neurological disorders, however, CSF typically yields more
accurate results (Freischmidt et al., 2013; Cloutier et al., 2015).
A meta-analysis examining data from over 20 original works
on CNS malignancies found that CSF-based miRNA profile was
more sensitive and specific than blood-derived miRNA. In this
meta-analysis, the sensitivity for detecting CNS malignancies
increased from 83% for blood-derived miRNA to 86% for CSF
miRNA while the specificity increased from 81% in blood to 88%
in CSF (Wei et al., 2015).
Blood volume is greater than CSF volume and thus, miRNA
concentration is diluted when the nucleotide sequences cross
from the CSF through the blood-brain barrier (BBB) and into the
blood. This dilution process leads to less clarity in the diagnostic
findings. Furthermore, while CSF contains miRNAs shed directly
from the brain, blood contains miRNAs shed from all bodily
tissues. For example, peripheral tissues excrete large amounts of
miR-21 that can interfere with the diagnosis CNS tumors which
also excrete miR-21 (Akers et al., 2013). In the case of miR-
21 excreting CNS tumors, CSF sampling is therefore preferred.
While certain miRNA exist in both blood and CSF, they are
often poorly correlated. Furthermore, other miRNA subtypes
have been exclusively identified in CSF or blood. Burgos et al.
also compared microRNA present in serum and CSF from five
subjects, and the study revealed that profiles of microRNA are
more similar from different subjects for either CSF or serum and
are less similar to one another, even within the same subject. The
reasoning of this finding is due to microRNAs in CSF are derived
from neural cells, whereas serum microRNAs are collected from
all tissues in the body. The authors concluded based on the
results, that while there are a large number of microRNA unique
to CSF and serum, most miRNAs are present in both of them
(Burgos et al., 2013). Also, sequencing small RNAs from small
volumes can provide a large amount of reproducible data.
Early studies seem to suggest that the BBB plays a minor
role in dictating the passage of miRNA between CSF and
blood. The BBB becomes more permeable as a result of the
inflammatory component of many neurodegenerative diseases.
This process is not well understood and it seems at baseline
that the BBB could still have residual effects in preventing the
mixing of CSF and blood (Blennow et al., 1990; Berzin et al.,
2000; Begley and Brightman, 2003; Zipser et al., 2007; Cheng
et al., 2013). Other sources of miRNA such as urine, milk, and
saliva may be less invasive and cost-effective (Cheng et al., 2013;
Sheinerman and Umansky, 2013). However, they may contain
more contaminants. Urine, for example, tends to be very rich
in cells and can contain microorganisms in addition to renal,
hematologic, and other cellular debris, providing insufficient or
unsatisfactory data (Cheng et al., 2013).
DISCUSSION
CNS Degenerative Diseases
Abnormal CSF miRNA profiles could diagnose various CNS
disorders, such as AD. Cogswell et al. was one of the earliest to
discover that CSF miRNA profiles could differentiate AD from
control patients. CSF was isolated from 20 donors, including
Braak Stage 5 (severe AD) and Braak Stage 1 (nondemented
controls). MiR-27a, miR-125b, miR-146, and 57 others were
significantly upregulated or downregulated in the Braak 5
population relative to the Braak 1 population. These dysregulated
miRNAs were found to be involved in immune cell function, T
cell signaling, and T cell activation (Cogswell et al., 2008).
Recent studies have validated the use of CSF miRNA in
AD detection. Galimberti et al. studied 22 AD patients and 18
Non-inflammatory neurological disease controls (NINDC). In
a confirmatory study, they evaluated 15 AD and 12 NINDC
patients. They found significantly decreased levels of CSF
miR-125b and miR-26b in AD patients compared to controls
(Galimberti et al., 2014). Likewise, miR-802, which is located in
the RUNX1 gene (greatly overexpressed in AD) has been shown
to be correlated with early AD (van Harten et al., 2011).
Galimberti et al. reported a negative correlation of CSF miR-
26b with total and phosphorylated Tau (T-Tau and P-Tau) levels
in AD patients (Galimberti et al., 2014). Sala et al. analyzed 8
miRNAs from 2 age-matched cohorts and found 1-fold lower CSF
miR-27a-3p expression and 1-fold higher miR-216a-5p and miR-
210 expression in AD patients. Levels of these miRNA were also
correlated with T-tau and P-tau values (Sala Frigerio et al., 2013).
It is encouraging that many of these CSF miRNAs correlate with
proteins that are virtually pathognomonic for AD such as Tau and
Aβ. The dysregulation of miR-29b and miR-125b were further
studied in the CSF of 18 AD patients and 20 healthy controls
using quantitative PCR. CSF miR-29a levels were increased by a
factor of 2.2 in AD patients when compared to controls (Müller
et al., 2015). MiR-29a is thought to play a part in the formation of
BACE1, a key enzyme involved in Aβ amyloid formation (Hébert
et al., 2008). AD differentiation from healthy controls using miR-
29a as a biomarker had 89% sensitivity and 70% specificity.
MiR-125b expression was slightly increased, with 78% sensitivity
and 60% specificity in differentiating AD patients from controls
(Müller et al., 2015). MiR-125b is thought to be involved in the
cell growth and differentiation pathway via Hedgehog signaling
(Ferretti et al., 2008).
Given new evidence for its potential role in hypoxic injury
and VEGF (an angiogenic growth factor) mediated disease,
miR-210 expression was quantified in 56 patients with mild
cognitive impairment (MCI) and AD when compared to 42
healthy controls using quantitative PCR (Solerte et al., 2005; Liu
et al., 2014; Zhu et al., 2015). DecreasedmiR-210 and VEGF levels
were correlated with the degree of dementia and disease severity
(Zhu et al., 2015).
One of the largest studies investigating Parkinson’s disease
(PD) and AD miRNA biomarkers was conducted in 2014 by
Burgos et al. CSFmiRNA profiles and post-mortem biopsies were
studied in 69 patients with AD, 67 PD patients, and 78 healthy
controls using next generation sequencing. Forty-one CSF
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miRNAs were downregulated in AD patients when compared to
controls. Seventy-three percent of the dysregulated miRNAs have
been previously linked to AD, showing reproducibility amongst
miRNA studies. When compared to PD patients, only miR-32-5p
was found to be unique to AD. Seventeen miRNAs were found to
be dysregulated and 14 downregulated in the CSF of PD patients
compared to controls. Additionally, decreased CSF expression of
miR-9-3p and miR-708-3p correlated with an increased Braak
score. MiR-101-3p was also linked to amyloid precursor protein
(APP) expression and Tau phosphorylation. Furthermore, Lewy
body pathology progression was found to be linked to higher
miR-34a-5p and miR-374a-5p CSF expression (Burgos et al.,
2014).
In addition to AD, CSF miRNA has also been studied in
amyotrophic lateral sclerosis (ALS). De Felice et al. examined
CSF miRNA from 10 sporadic ALS (sALS) patients and 10
controls using qRT-PCR. Several CSF miRNA were differentially
expressed in sALS patients relative to controls, including miR-
338-3p (De Felice et al., 2014). MiR-388-3p is of particular
interest because it had been previously shown to be upregulated
in frontal cortex tissues, blood, leukocytes, serum, and spinal
cord tissues (Shioya et al., 2010; De Felice et al., 2014; Cloutier
et al., 2015). In addition, MiR-338-3p has been speculated to be
involved in many neuronal functions, including neuroblast and
mature neuron apoptosis as well as neuronal metabolic pathway
regulation (Aschrafi et al., 2008; Ragusa et al., 2010). Elevation
of other miRNAs, such as CSF miR-27b, miR-146a, and miR-
532-3p, cannot only be used to recognize ALS but also enable
the differentiation of ALS from multiple sclerosis (Cloutier et al.,
2015).
Freischmidt et al. also found a strong link between
dysregulated miRNA and TDP-43 in ALS patients. Freischmidt
analyzed the CSF miRNA from 22 sALS patients and 24 control
subjects and found that 5 out of 9 miRNA associated with TDP-
43 were dysregulated in the CSF of ALS patients. MiR-132-5p,
miR-132-3p, miR-143-3p were upregulated while miR-143-5p
and miR-574-5p were downregulated (Freischmidt et al., 2013).
TDP-43 is a central player in ALS pathogenesis and therefore
its linkage with miRNAs makes miRNA even more credible as
a biomarker.
Lastly, CSF miRNA profile has been examined in multiple
sclerosis (MS). CSF miRNA expression was studied in 53
MS patients and 39 controls. MiR-181c and miR-633 were
upregulated and miR-922 was downregulated in MS patients
when compared to controls. When combined, miR-633
and miR-922 was 88% sensitive and 69% specific in MS
diagnosis. Additionally, miR-181c and miR-633 could be used
to differentiate relapsing-remitting (RRMS) and secondary
progressive MS (SPMS) courses with a specificity of 82%
specificity and sensitivity of 69%. These miRNA levels were
increased in RRMS when compared to SPMS, but were expressed
at higher levels in all MS cases compared to controls (Haghikia
et al., 2012; See Table 1).
Other Conditions
Beyond neurodegenerative disorders, CSF miRNA profiles have
been explored in CNS malignancies. In a study examining 23
TABLE 1 | Potential microRNA biomarkers identified in plasma and
Cerebrospinal Fluid (CSF) in different neurodegenerative diseases.
Disorder Increased Decreased
Alzheimer’s disease miR-29aa,b, miR-210c,d,e,
miR-216ac,d, miR-802f
miR-9g, miR-26ba,h,
miR-27aa,c,d, miR-125ba,b,h
Parkinson’s disease Overall downregulation
Amyotrophic lateral
sclerosis
miR-338-3pi
143-5pj
132-3p, 132-5p, 143-3p,
let-7bj,k
Multiple sclerosis miR-181c, miR-633 miR-633 + miR-922
aKiko et al. (2014); bMüller et al. (2015); cCogswell et al. (2008); dSala Frigerio et al. (2013);
eZhu et al. (2015); f van Harten et al. (2011); gBurgos et al. (2014); hGalimberti et al. (2014);
iDe Felice et al. (2014); jFreischmidt et al. (2013); kCloutier et al. (2015).
primary CNS lymphoma (PCNSL) patients and 30 controls
and a follow-up with 16 additional PCNSL patients, Baraniskin
et al. found that miR-21, miR-19b, and miR-92 were among the
most highly upregulated miRNA in PCNSL (Baraniskin et al.,
2011). These miRNA had a95.7–97.4% sensitivity and 96.7%
specificity for PCNSL and could also differentiate PCNSL from
inflammatory CNS disorders. In addition, these miRNA were
found to correlate with tumor volume on MRI, as well as disease
progression, remission, and relapse in response to chemotherapy
(Baraniskin et al., 2011, 2012a). Of the 3 upregulated miRNA,
miR-21 was the most highly elevated, with a relative expression
level of 60.0 in PCNSL and 3.8 in controls (Baraniskin et al.,
2011). MiR-21 is upregulated in a variety of CNS tumors,
possibly because of its role in targeting tumor suppressors Acidic
Nuclear Phosphoprotein 32 Family, Member A (ANP32A) and
SWI/SNF-related, Matrix-associated, Actin-dependent Regulator
Chromatin group A (SMARCA4) (Akers et al., 2013).
CSF miRNA profiling has also been explored in gliomas
and glioblastomas. Like PCNSL, gliomas are characterized by
miR-21 over-expression, with a 85–87% sensitivity and 93–
100% specificity in glioblastoma detection (Gabriely et al., 2008;
Baraniskin et al., 2012a; Akers et al., 2013). Akers et al. reported a
decreased miR-21 level of more than 50-fold in a surgical patient
as compared to pre-surgery level, suggesting that miR-21 can
potentially be used to determine treatment efficacy (Akers et al.,
2013). Furthermore, low expression of MiR-10b was found in
normal individuals, and high expression was noted in roughly
90% of glioma subjects. Additionally, miR-10b correlates well
with erlotinib treatment, CSF cytology, andMRI results (Teplyuk
et al., 2012). Finally, miR-15b, can detect glioma with a 90%
sensitivity and 94.9% specificity alone or a 90% sensitivity and
100% specificity when measured along with miR-21 (Baraniskin
et al., 2012b).
In addition to cancers and neurodegenerative diseases, brain
injuries and infections can also potentially be detected by
CSF miRNA profiling. Traumatic brain injuries (TBI), for
example, are associated with elevated miR-let-7i and miR-
451, which are thought to produce TBI-associated damages
through the action of cytokines S100b and UCH L1. TBIs are
also associated with decreased miR-9 levels and higher overall
CSF miRNA levels (Balakathiresan et al., 2012; Patz et al.,
2013). HIV encephalitis (HIVE) patients, while they do not
exhibit any higher overall CSF miRNA, do show increased
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levels of miR-937, miR-598 and miR-595 (Pacifici et al., 2013).
Moreover, stroke patients have been shown to exhibit elevated
miR-let-7c and miR-221-3p (Sørensen et al., 2014). Psychiatric
conditions, such as major depressive disorder (MDD), may
also benefit from CSF miRNA detection Notably, miR-221-
3p, miR-34a-5p, and miR-let-7d-3p levels were upregulated
and miR-451 was downregulated with a sensitivity of 84.85–
96.88% and specificity of 90.48–95.24% for MDD (Wan et al.,
2015).
FUTURE DIRECTIONS
MiRNA CSF profiling may lead to early diagnosis of disease,
allowing for early prevention implementation and timely
treatment of many disorders. For example, diffuse neuronal
damage in TBI may be identified using miRNA biomarkers when
CT scans are negative (Balakathiresan et al., 2012; Rao et al.,
2013). MiRNA may also guide prognosis and help determine
the aggressiveness of the required treatment, such as suicide
risk-stratification in MDD or tumor staging (Baraniskin et al.,
2012a; Wan et al., 2015). Longitudinal miRNA examination may
allow for tracking of disease progression and treatment efficacy
(Baraniskin et al., 2012a). These, and many other applications of
miRNA CSF profiling have yet to be fully explored.
Altered miRNA expression has been noted in the serum
and brain tissue samples of patients with frontotemporal
dementia, progressive supranuclear palsy, bipolar affective
disorder, addiction/substance abuse, anxiety disorders, autism,
Tourette’s syndrome, postoperative delirium, oligodendroma,
astrocytoma and medulloblastoma. Specific miRNA have also
been implicated in some of these disease processes, and show
promise for further examination as CSF biomarkers (De Smaele
et al., 2010; Chan and Kocerha, 2012; Stoicea et al., 2013; Kolshus
et al., 2014; Ruggeri et al., 2014). Additionally, miRNA CSF
have been studied in schizophrenia, but the small sample size
precluded comparison between diseased and control CSF levels
(Gallego et al., 2012).
A meta-analysis concluded that the strongest singular CSF
miRNA biomarker for glioma, miR-21, achieved 82% sensitivity
and 94% specificity. However, pooled results of all miRNA
studied and taken as a diagnostic panel, had a sensitivity of 91%
sensitivity and specificity of 94% (Qu et al., 2015). Additionally,
miRNA combinations are sometimes required to differentiate
one particular CNS disease from another since miRNAs have
such widespread action. While increased miR-21 and miR-
10b are indicative of various types of brain cancer, relatively
increased miR-200 signifies metastasis over primary tumor.
When 7 miRNAs (miR-10b, miR-21, miR-125b, miR-141, and
several miR-200s) were studied as a panel, diagnostic probability
was higher at 99% than single biomarkers (Teplyuk et al., 2012).
Many studies searched miRNA gene banks to connect
miRNAs with disease-related proteins. Matches either supported
previously hypothesized disease processes or proposed new
processes (Gabriely et al., 2008; Hébert et al., 2008; Robertus
et al., 2009; Medina et al., 2010; Balakathiresan et al., 2012;
Wan et al., 2015). Continued research on miRNA and its
function may further elucidate miRNA links to disease pathology
and disease-causing genetic imbalances could be restored with
miRNA-targeted treatment (Baraniskin et al., 2012b;Müller et al.,
2015; Wan et al., 2015; Zhu et al., 2015). Oved et al. concluded
that treatment of human cell tissue lines with paroxetine
decreasedmiR-221 andmiR-222 (Oved et al., 2013). Additionally,
miravirsen, an anti-miR-122 treatment, is currently in Phase 2
clinical trials for the treatment of chronic hepatitis C (Kolshus
et al., 2014).
Although this review presents strong evidence for the clinical
importance of CSF biomarkers, there are a few limitations.
Among the various studies, there was significant control group
variation in number, as CSF can be difficult to obtain in healthy
individuals (Baraniskin et al., 2011, 2012b; Haghikia et al., 2012;
Sørensen et al., 2014; Müller et al., 2015; Zhu et al., 2015). Also,
there isn’t a control group data base for miRNA expression
that would normalize background variability for disease profile
comparison. Additionally, most of the studies had small sample
sizes, some with as few as 6 patients (Sørensen et al., 2014). Larger
scale and longitudinal studies must be completed to further
validate these results before clinical integration. Repetition
would also help identify the most sensitive and specific miRNA
biomarkers, as some studies show differing results, potentially
from varying methods of analysis (Cogswell et al., 2008; Müller
et al., 2015; Zhu et al., 2015). Furthermore, it should be noted
that certain medications, including some anesthetics, can affect
miRNA levels and potentially complicate results (Ackermann
et al., 2014). Finally, lumbar puncture is not currently standard
diagnostic procedure for many of these conditions, including
PCNSL, glioma, TBI and depression (Baraniskin et al., 2011,
2012b; Balakathiresan et al., 2012; Wan et al., 2015).
Additionally, various methods are used in miRNA
acquisition, extraction, amplification, processing, quantification,
normalization and statistical analysis. This is even further
complicated since miRNA’s stability allows analysis from
preserved, frozen, and fresh tissues and fluids (Xi et al., 2007;
Weber et al., 2010). However, sample quality, time elapsed since
collection, and storage methods can all affect results (De Smaele
et al., 2010). The various extraction methods and reagents used
yield different miRNA levels and profiles (Eldh et al., 2012).
Further discrepancies may result from the multitude of data
processing software and data normalization techniques available
for use (Meyer et al., 2010; Garber et al., 2011).
Although new techniques are being developed, there are
three major approaches to miRNA-specific quantification:
quantitative reverse transcription polymerase chain reaction
(qrPCR), hybridization-based methods using arrays, and high-
throughput sequencing or next generation sequencing (nextgen).
Each technique has its own strengths and weaknesses. QrPCR
provides the most accurate absolute miRNA quantification
and is already widely used in DNA and RNA processing.
However, reaction conditions can differ between machines and
samples, and it is not ideal for novel miRNA identification.
This is the least expensive miRNA analysis method (Pritchard
et al., 2012). Microarrays of fluorescent probes or beads are
best used to compare miRNA levels between samples, but are
less accurate, sensitive, and reliable for absolute quantification
because non-identical sequences can hybridize (Pritchard et al.,
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2012). This well-established method requires a larger amount of
starting miRNA (De Smaele et al., 2010). Nextgen is a promising
new technique that measures relative miRNA expression, as
opposed to direct absolute quantification. It can accurately
differentiate similar miRNAs and identify novel miRNA. Nextgen
quantification is also able to yield a massive amount of data
for computation. Methods other than nextgen-like techniques
require previous knowledge about the miRNA in question, so
results can be limited and biased. As a new technology, nextgen is
the most expensive miRNA analysis method (Meyer et al., 2010)
CONCLUSION
Although a newly emerging field, CSF miRNA sampling and
expression profiling show promise as a noninvasive CNS
biomarker. MiRNAs exhibit widespread genetic action, playing
a role in many cellular functions, and have been linked to
pathological processes. MiRNA changes are often detectable
prior to their downstream protein expression effects. They are
protected and stable in various body fluids and tissues, making
them a valuable biomarker. While serum miRNA can be a
useful biomarker in various other diseases, the BBB might
preclude its use in the diagnosis of neurological disorders. CSF, a
promising alternative, is a relatively cell- andmicroorganism-free
fluid.
The CNS is the least surgically accessible body system, making
diagnosis of disorders invasive, costly, and potentially dangerous.
Lumbar puncture is already part of the diagnostic workup of
many neurodegenerative diseases including AD and PD. That
being said, miRNA CSF profiling would be relatively easy to
integrate into the management of these diseases. However,
the current diagnostic workup of psychiatric disorders and
brain cancers relies primarily on clinical examination and
invasive brain biopsy. While currently, miRNA CSF profiling
focuses mainly on disease identification, there are numerous
other applications including prognosis, course tracking, and
potential treatment of CNS diseases. Alongside patient history,
physical exam, and clinical testing, miRNA profiles have
the potential to contribute positively to patient care and
outcomes.
AUTHOR CONTRIBUTIONS
The authors declare equal contribution in the writing, editing and
final version of the present manuscript.
ACKNOWLEDGMENTS
Nicholas Joseph from The Ohio State University Department of
Neuroscience contributed during the editing process.
REFERENCES
Ackermann, W., Stoicea, N., Wojda, T. R., Steiner, N., Barnett, C. J., and
Bergese, S. D. (2014). Does post-operative cognitive decline promote/accelerate
Alzheimer’s disease pathology? Perioperative cerebrospinal fluid biomarkers
and the gap of knowledge. Aust. J. Anesth. Anal. 2:1038.
Akers, J. C., Ramakrishnan, V., Kim, R., Skog, J., Nakano, I., Pingle, S., et al.
(2013). MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF):
a platform for glioblastoma biomarker development. PLoS ONE 8:e78115. doi:
10.1371/journal.pone.0078115
Alexandrov, P. N., Dua, P., Hill, J. M., Bhattacharjee, S., Zhao, Y., and Lukiw,
W. J. (2012). microRNA (miRNA) speciation in Alzheimer’s disease (AD)
cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol.
Biol. 3, 365–373.
Aschrafi, A., Schwechter, A. D., Mameza, M. G., Natera-Naranjo, O., Gioio,
A. E., and Kaplan, B. B. (2008). MicroRNA-338 regulates local cytochrome
c oxidase IV mRNA levels and oxidative phosphorylation in the axons of
sympathetic neurons. J. Neurosci. 28, 12581–12590. doi: 10.1523/JNEUROSCI.
3338-08.2008
Balakathiresan, N., Bhomia, M., Chandran, R., Chavko, M., McCarron, R. M., and
Maheshwari, R. K. (2012). MicroRNA let-7i is a promising serum biomarker
for blast-induced traumatic brain injury. J. Neurotrauma 29, 1379–1387. doi:
10.1089/neu.2011.2146
Baraniskin, A., Kuhnhenn, J., Schlegel, U., Chan, A., Deckert, M., Gold, R., et al.
(2011). Identification of microRNAs in the cerebrospinal fluid as marker for
primary diffuse large B-cell lymphoma of the central nervous system. Blood 117,
3140–3146. doi: 10.1182/blood-2010-09-308684
Baraniskin, A., Kuhnhenn, J., Schlegel, U., Maghnouj, A., Zöllner, H., Schmiegel,
W., et al. (2012b). Identification of microRNAs in the cerebrospinal fluid
as biomarker for the diagnosis of glioma. Neuro-oncology 14, 29–33. doi:
10.1093/neuonc/nor169
Baraniskin, A., Kuhnhenn, J., Schlegel, U., Schmiegel, W., Hahn, S., and Schroers,
R. (2012a). MicroRNAs in cerebrospinal fluid as biomarker for disease course
monitoring in primary central nervous system lymphoma. J. Neurooncol. 109,
239–244. doi: 10.1007/s11060-012-0908-2
Begley, D. J., and Brightman, M. W. (2003). Structural and functional aspects
of the blood-brain barrier. Prog. Drug Res. 6, 19–78. doi: 10.1007/978-3-034
8-8049-7_2
Berzin, T. M., Zipser, B. D., Rafii, M. S., Kuo-Leblanc, V., Yancopoulos, G. D.,
Glass, D. J., et al. (2000). Agrin and microvascular damage in Alzheimer’s
disease. Neurobiol. Aging 21, 349–355. doi: 10.1016/S0197-4580(00)
00121-4
Blennow, K., Wallin, A., Fredman, P., Karlsson, I., Gottfries, C. G., and
Svennerholm, L. (1990). Blood-brain barrier disturbance in patients with
Alzheimer’s disease is related to vascular factors. Acta Neurol. Scand. 81,
323–326. doi: 10.1111/j.1600-0404.1990.tb01563.x
Bonauer, A., Boon, R. A., and Dimmeler, S. (2010). Vascular micrornas. Curr. Drug
Targets 11, 943–949. doi: 10.2174/138945010791591313
Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon,
L., et al. (2014). SNAP-25 is a promising novel cerebrospinal fluid biomarker
for synapse degeneration in Alzheimer’s disease. Mol. Neurodegener. 9:53. doi:
10.1186/1750-1326-9-53
Burgos, K. L., Javaherian, A., Bomprezzi, R., Ghaffari, L., Rhodes, S.,
Courtright, A., et al. (2013). Identification of extracellular miRNA in human
cerebrospinal fluid by next-generation sequencing. RNA 19, 712–722. doi:
10.1261/rna.036863.112
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T.,
et al. (2014). Profiles of extracellular miRNA in cerebrospinal fluid and
serum from patients with Alzheimer’s and Parkinson’s diseases correlate
with disease status and features of pathology. PLoS ONE 9:e94839. doi:
10.1371/journal.pone.0094839
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., et al.
(2002). Frequent deletions and down-regulation of micro- RNA genes miR15
and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci.
U.S.A. 99, 15524–15529. doi: 10.1073/pnas.242606799
Chan, A. W., and Kocerha, J. (2012). The path to microRNA therapeutics
in psychiatric and neurodegenerative disorders. Front. Genet. 3:82. doi:
10.3389/fgene.2012.00082
Cheng, L., Quek, C. Y., Sun, X., Bellingham, S. A., and Hill, A. F. (2013).
The detection of microRNA associated with Alzheimer’s disease in biological
Frontiers in Genetics | www.frontiersin.org 6 February 2016 | Volume 7 | Article 11
Stoicea et al. MicroRNA as a CNS Biomarker
fluids using next-generation sequencing technologies. Front. Genet. 4:150. doi:
10.3389/fgene.2013.00150
Cloutier, F., Marrero, A., O’Connell, C., and Morin, P., Jr. (2015). MicroRNAs
as potential circulating biomarkers for amyotrophic lateral sclerosis. J. Mol.
Neurosci. 56,102–112. doi: 10.1007/s12031-014-0471-8
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008).
Identification of miRNA changes in Alzheimer’s disease brain and CSF yields
putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 14,
27–41.
Czeiter, E., Mondello, S., Kovacs, N., Sandor, J., Gabrielli, A., Schmid, K.,
et al. (2012). Brain injury biomarkers may improve the predictive power
of the IMPACT outcome calculator. J. Neurotrauma 29, 1770–1778. doi:
10.1089/neu.2011.2127
De Felice, B., Annunziata, A., Fiorentino, G., Borra, M., Biffali, E., Coppola, C.,
et al. (2014). miR-338-3p is over-expressed in blood, CFS, serum and spinal
cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics 15,
243–253. doi: 10.1007/s10048-014-0420-2
De Smaele, E., Ferretti, E., and Gulino, A. (2010). MicroRNAs as biomarkers
for CNS cancer and other disorders. Brain Res. 133, 800–811. doi:
10.1016/j.brainres.2010.03.103
Eldh, M., Lötvall, J., Malmhäll, C., and Ekström, K. (2012). Importance of
RNA isolation methods for analysis of exosomal RNA: evaluation of different
methods.Mol. Immunol. 50, 278–286. doi: 10.1016/j.molimm.2012.02.001
Ferretti, E., De Smaele, E., Miele, E., Laneve, P., Po, A., Pelloni, M., et al.
(2008). Concerted microRNA control of Hedgehog signalling in cerebellar
neuronal progenitor and tumour cells. EMBO J. 27, 2616–2627. doi:
10.1038/emboj.2008.172
Freischmidt, A., Müller, K., Ludolph, A. C., and Weishaupt, J. H. (2013). Systemic
dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis.
Acta Neuropathol. Commun. 1:42. doi: 10.1186/2051-5960-1-42
Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley,
P. S., et al. (2008). MicroRNA 21 promotes glioma invasion by targeting
matrix metalloproteinase regulators. Mol. Cell. Biol. 28, 5369–5380. doi:
10.1128/MCB.00479-08
Galimberti, D., Villa, C., Fenoglio, C., Serpente, M., Ghezzi, L., Cioffi, S. M., et al.
(2014). Circulating miRNAs as potential biomarkers in Alzheimer’s disease.
J. Alzheimers. Dis. 42, 1261–1267. doi: 10.1016/j.jalz.2014.05.278
Gallego, J. A., Gordon, M. L., Claycomb, K., Bhatt, M., Lencz, T., and Malhotra, A.
K. (2012). In vivomicroRNA detection and quantitation in cerebrospinal fluid.
J. Mol. Neurosci. 47, 243–248. doi: 10.1007/s12031-012-9731-7
Garber, M., Grabherr, M. G., Guttman,M., and Trapnell, C. (2011). Computational
methods for transcriptome annotation and quantification using RNA-seq. Nat.
Methods 8, 469–477. doi: 10.1038/nmeth.1613
Ghidoni, R., Benussi, L., Paterlini, A., Albertini, V., Binetti, G., and Emanuele, E.
(2011). Cerebrospinal fluid biomarkers for Alzheimer’s disease: the present and
the future. Neurodegener. Dis. 8, 413–420. doi: 10.1159/000327756
Guan, Y., Mizoguchi, M., Yoshimoto, K., Hata, N., Shono, T., Suzuki, S. O.,
et al. (2010). MiRNA-196 is upregulated in glioblastoma but not in anaplastic
astrocytoma and has prognostic significance. Clin. Cancer Res. 16, 4289–4297.
doi: 10.1158/1078-0432.CCR-10-0207
Haghikia, A., Haghikia, A., Hellwig, K., Baraniskin, A., Holzmann, A., Decard,
B. F., et al. (2012). Regulated microRNAs in the CSF of patients with
multiple sclerosis: a case-control study. Neurology 79, 2166–2170. doi:
10.1212/WNL.0b013e3182759621
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W.,
Silahtaroglu, A. N., et al. (2008). Loss of microRNA cluster miR-29a/b-1
in sporadic Alzheimer’s disease correlates with increased BACE1/beta-
secretase expression. Proc. Natl. Acad. Sci. U.S.A. 105, 6415–6420. doi:
10.1073/pnas.0710263105
Hoglund, K., Fourier, A., Perret-Liaudet, A., Zetterberg, H., Blennow, K., and
Portelius, E. (2015). Alzheimer’s disease - Recent biomarker developments
in relation to updated diagnostic criteria. Clin. Chim. Acta 44, 9–8. doi:
10.1016/j.cca.2015.01.041
Humpel, C. (2011). Identifying and validating biomarkers for Alzheimer’s disease.
Trends Biotechnol. 29, 26–32. doi: 10.1016/j.tibtech.2010.09.007
Kern, S., Skoog, I., Borjesson-Hanson, A., Blennow, K., Zetterberg, H., Ostling,
S., et al. (2014). Higher CSF interleukin-6 and CSF interleukin-8 in current
depression in older women. Results from a population-based sample. Brain
Behav. Immun. 4, 15–18. doi: 10.1016/j.bbi.2014.05.006
Kiko, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., and Miyazawa, T.
(2014). MicroRNAs in plasma and cerebrospinal fluid as potential markers for
Alzheimer’s disease. J. Alzheimers. Dis. 39, 253–259. doi: 10.3233/JAD-130932
Kim, D. H., Yeo, S. H., Park, J. M., Choi, J. Y., Lee, T. H., Park, S. Y., et al. (2014).
Genetic markers for diagnosis and pathogenesis of Alzheimer’s disease. Gene
545, 185–193. doi: 10.1016/j.gene.2014.05.031
Kolshus, E., Dalton, V. S., Ryan, K. M., and McLoughlin, D. M. (2014). When
less is more–microRNAs and psychiatric disorders. Acta Psychiatr. Scand. 129,
241–256. doi: 10.1111/acps.12191
Ksiazek-Winiarek, D. J., Kacperska, M. J., and Glabinski, A. (2013). MicroRNAs as
novel regulators of neuroinflammation. Mediators Inflamm. 201, 372351. doi:
10.1155/2013/172351
Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson,
K., et al. (2014). Cerebrospinal fluid levels of the synaptic protein neurogranin
correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers
Dement. 11, 1180–1190. doi: 10.1016/j.jalz.2014.10.009
Lehmann, S. M., Krüger, C., Park, B., Derkow, K., Rosenberger, K., Baumgart,
J., et al. (2012). An unconventional role for miRNA: let-7 activates Toll-like
receptor 7 and causes neurodegeneration. Nat. Neurosci. 15, 827–835. doi:
10.1038/nn.3113
Liu, P., Li, Y.W.,Wang, X. S., Zou, X., Zhang, D. Z.,Wang, D. X., et al. (2013). High
serum interleukin-6 level is associated with increased risk of delirium in elderly
patients after noncardiac surgery: a prospective cohort study. Chin. Med. J. 126,
3621–3627.
Liu, S. C., Chuang, S. M., Hsu, C. J., Tsai, C. H., Wang, S. W., and Tang,
C. H. (2014). CTGF increases vascular endothelial growth factor-dependent
angiogenesis in human synovial fibroblasts by increasing miR-210 expression.
Cell Death Dis. 5:e1485. doi: 10.1038/cddis.2014.453
Maxeiner, H. G., Marion Schneider, E., Kurfiss, S. T., Brettschneider, J., Tumani,
H., and Bechter, K. (2014). Cerebrospinal fluid and serum cytokine profiling
to detect immune control of infectious and inflammatory neurological
and psychiatric diseases. Cytokine 69, 62–67. doi: 10.1016/j.cyto.2014.
05.008
Medina, P. P., Nolde, M., and Slack, F. J. (2010). OncomiR addiction in an in vivo
model of microRNA-21-induced pre-B-cell lymphoma. Nature 467, 86–90. doi:
10.1038/nature09284
Meyer, S. U., Pfaﬄ, M. W., and Ulbrich, S. E. (2010). Normalization strategies
for microRNA profiling experiments: a ‘normal’ way to a hidden layer of
complexity? Biotechnol. Lett. 32, 1777–1788. doi: 10.1007/s10529-010-0380-z
Müller, M., Jäkel, L., Bruinsma, I. B., Claassen, J. A., Kuiperij, H. B., and Verbeek,
M. M. (2015). MicroRNA-29a is a candidate biomarker for Alzheimer’s disease
in cell-free cerebrospinal fluid. Mol. Neurobiol. doi: 10.1007/s12035-015-9156-
8. [Epub ahead of print].
Oved, K., Morag, A., Pasmanik-Chor, M., Rehavi, M., Shomron, N., and Gurwitz,
D. (2013). Genome-wide expression profiling of human lymphoblastoid cell
lines implicates integrin beta-3 in the mode of action of antidepressants. Transl.
Psychiatry 3:e313. doi: 10.1038/tp.2013.86
Pacifici, M., Delbue, S., Ferrante, P., Jeansonne, D., Kadri, F., Nelson, S., et al.
(2013). Cerebrospinal fluid miRNA profile in HIV-encephalitis. J. Cell. Physiol.
228, 1070–1075. doi: 10.1002/jcp.24254
Patz, S., Trattnig, C., Grunbacher, G., Ebner, B., Gülly, C., Novak, A., et al.
(2013). More than cell dust: microparticles isolated from cerebrospinal
fluid of brain injured patients are messengers carrying mRNAs,
miRNAs, and proteins. J. Neurotrauma 30, 1232–1242. doi: 10.1089/neu.
2012.2596
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L.,
et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the
“McDonald Criteria.” Ann. Neurol. 58, 840–846. doi: 10.1002/ana.20703
Pritchard, C. C., Cheng, H. H., and Tewari, M. (2012). MicroRNA profiling:
approaches and considerations. Nat. Rev. Genet. 13, 358–369. doi:
10.1038/nrg3198
Pyykö, O., Lumela, M., Rummukainen, J., Nerg, O., Seppälä, T. T., Herukka,
S., et al. (2014). Cerebrospinal fluid biomarker and brain biopsy findings
in idiopathic normal pressure hydrocephalus. PLoS ONE 9:e91974. doi:
10.1371/journal.pone.0091974
Frontiers in Genetics | www.frontiersin.org 7 February 2016 | Volume 7 | Article 11
Stoicea et al. MicroRNA as a CNS Biomarker
Qu, S., Guan, J., and Liu, Y. (2015). Identification of microRNAs as novel
biomarkers for glioma detection: a meta-analysis based on 11 articles. J. Neurol.
Sci. 348, 181–187. doi: 10.1016/j.jns.2014.11.036
Ragusa, M., Majorana, A., Banelli, B., Barbagallo, D., Statello, L., Casciano,
I., et al. (2010). MIR152, MIR200B, and MIR338, human positional and
functional neuroblastoma candidates, are involved in neuroblast differentiation
and apoptosis. J. Mol. Med. 88, 1041–1053. doi: 10.1007/s00109-010-
0643-0
Rao, P., Benito, E., and Fischer, A. (2013). MicroRNAs as biomarkers for CNS
disease. Front. Mol. Neurosci. 6:39. doi: 10.3389/fnmol.2013.00039
Robertus, J. L., Harms, G., Blokzijl, T., Booman, M., de Jong, D., van Imhoff,
G., et al. (2009). Specific expression of miR-17-5p and miR-127 in testicular
and central nervous system diffuse large B-cell lymphoma. Mod. Pathol. 22,
547–555. doi: 10.1038/modpathol.2009.10
Rosén, C., Farahmand, B., Skillbäck, T., Nägga, K., Mattsson, N., Kilander, L.,
et al. (2015). Benchmarking biomarker-based criteria for Alzheimer’s disease:
data from the Swedish Dementia Registry, SveDem. Alzheimers Dement. 11,
1470–1479. doi: 10.1016/j.jalz.2015.04.007
Ruggeri, B., Sarkans, U., Schumann, G., and Persico, A. M. (2014). Biomarkers
in autism spectrum disorder: the old and the new. Psychopharmacology 231,
1201–1216. doi: 10.1007/s00213-013-3290-7
Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe,
R., et al. (2013). Reduced expression of hsa-miR-27a-3p in CSF
of patients with Alzheimer disease. Neurology 81, 2103–2106. doi:
10.1212/01.wnl.0000437306.37850.22
Schramedei, K., Mörbt, N., Pfeifer, G., Läuter, J., Rosolowski, M., Tomm, J. M.,
et al. (2011). MicroRNA-21 targets tumor suppressor genes ANP32A and
SMARCA4. Oncogene 30, 2975–2985. doi: 10.1038/onc.2011.15
Scollato, A., Terreni, A., Caldini, A., Salvadori, B., Gallina, P., Francese, S., et al.
(2010). CSF proteomic analysis in patients with normal pressure hydrocephalus
selected for the shunt: CSF biomarkers of response to surgical treatment.
Neurol. Sci. 31, 283–291. doi: 10.1007/s10072-009-0181-0
Sheinerman, K. S., and Umansky, S. R. (2013). Circulating cell-free microRNA
as biomarkers for screening, diagnosis and monitoring of neurodegenerative
diseases and other neurologic pathologies. Front. Cell. Neurosci. 7:150. doi:
10.3389/fncel.2013.00150
Shioya, M., Obayashi, S., Tabunoki, H., Arima, K., Saito, Y., Ishida, T., et al.
(2010). Aberrant microRNA expression in the brains of neurodegenerative
diseases: miR-29a decreased in Alzheimer disease brains targets neurone
navigator 3. Neuropathol. Appl. Neurobiol. 36, 320–330. doi: 10.1111/j.1365-
2990.2010.01076.x
Siegel, S. R., Mackenzie, J., Chaplin, G., Jablonski, N. G., and Griffiths, L. (2012).
Circulating microRNAs involved in multiple sclerosis. Mol. Biol. Rep. 39,
6219–6225. doi: 10.1007/s11033-011-1441-7
Solerte, S. B., Ferrari, E., Cuzzoni, G., Locatelli, E., Giustina, A., Zamboni, M.,
et al. (2005). Decreased release of the angiogenic peptide vascular endothelial
growth factor in Alzheimer’s disease: recovering effect with insulin and
DHEA sulfate. Dement. Geriatr. Cogn. Disord. 19, 1–10. doi: 10.1159/0000
80963
Sørensen, S., Nygaard, A.−B., Nielsen, M.−Y., Jensen, K., and Christensen, T.
(2014). miRNA expression profiles in cerebrospinal fluid and blood of patients
with acute ischemic stroke. Transl. Stroke Res. 5, 711–718. doi: 10.1007/s12975-
014-0364-8
Stoicea, N., Wilson, T., Chandrasekhar, K., and Bergese, S. D. (2013). The role of
microRNAs as potential biomarkers in central nervous system disorders. Int. J.
Clin. Anesthesiol. 1:1009. doi: 10.3389/fnmol.2013.00039
Teplyuk, N.M., Mollenhauer, B., Gabriely, G., Giese, A., Kim, E., Smolsky,M., et al.
(2012). MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic
brain cancers and reflect disease activity. Neuro-oncology 14, 689–700. doi:
10.1093/neuonc/nos074
TheALSAssociation. (2015). Symptoms andDiagnosis: The ALSAssociation; 2015
[cited 2015 October 16, 2015]. Available online at: http://www.alsa.org/about-
als/symptoms.html
van den Boogaard, M., Kox, M., Quinn, K. L., van Achterberg, T., van der
Hoeven, J. G., Schoonhoven, L., et al. (2011). Biomarkers associated with
delirium in critically ill patients and their relation with long-term subjective
cognitive dysfunction; indications for different pathways governing delirium
in inflamed and noninflamed patients. Crit Care 15, R297. doi: 10.1186/
cc10598
van Harten, A., Mulders, J., Çevik, C., Kester, M., Scheltens, P., van der
Flier, W., et al. (2011). “MicroRNA analysis in the spinal fluid of
Alzheimer patients: a methodological feasibility study,” in Circulating Nucleic
Acids in Plasma and Serum, ed P. B. Gahan (Dordrecht: Springer),
275–282.
van Munster, B. C., Korevaar, J. C., Zwinderman, A. H., Levi, M., Wiersinga, W.
J., and De Rooij, S. E. (2008). Time-course of cytokines during delirium in
elderly patients with hip fractures. J. Am. Geriatr. Soc. 56, 1704–1709. doi:
10.1111/j.1532-5415.2008.01851.x
Wan, Y., Liu, Y., Wang, X., Wu, J., Liu, K., Zhou, J., et al. (2015).
Identification of differential MicroRNAs in cerebrospinal fluid and serum
of patients with major depressive disorder. PLoS ONE 10:e0121975. doi:
10.1371/journal.pone.0121975
Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., Huang, K. H., Lee, M. J., et al.
(2010). The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733–1741.
doi: 10.1373/clinchem.2010.147405
Wei, D., Wan, Q., Li, L., Jin, H., Liu, Y., Wang, Y., et al. (2015). MicroRNAs
as potential biomarkers for diagnosing cancers of central nervous system: a
meta-analysis.Mol. Neurobiol. 51, 1452–1461. doi: 10.1007/s12035-014-8822-6
Xi, Y., Nakajima, G., Gavin, E., Morris, C. G., Kudo, K., Hayashi, K., et al. (2007).
Systematic analysis of microRNA expression of RNA extracted from fresh
frozen and formalin-fixed paraffin-embedded samples. RNA 13, 1668–1674.
doi: 10.1261/rna.642907
Zhu, Y., Li, C., Sun, A., Wang, Y., and Zhou, S. (2015). Quantification
of microRNA-210 in the cerebrospinal fluid and serum: implications for
Alzheimer’s disease. Exp. Ther. Med. 9, 1013–1017. doi: 10.3892/etm.
2015.2179
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R.,
Hulette, C. M., et al. (2007). Microvascular injury and blood-brain
barrier leakage in Alzheimer’s disease. Neurobiol. Aging. 28, 977–986. doi:
10.1016/j.neurobiolaging.2006.05.016
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Stoicea, Du, Lakis, Tipton, Arias-Morales and Bergese. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Genetics | www.frontiersin.org 8 February 2016 | Volume 7 | Article 11
